Latest Administration News

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Australian Ethical reported a slight 1% decline in funds under management to $14.08 billion for December 2025, balancing positive retail flows against institutional mandate losses and market headwinds.

Eastern Metals Limited has responded to ASX concerns over delayed disclosure of director interest changes, attributing the lapse to end-of-year administrative challenges while affirming its compliance framework remains robust.

Southern Cross Gold Consolidated Ltd. has achieved a pivotal regulatory milestone enabling underground exploration at its Sunday Creek project, backed by strong drilling results and a robust cash position of $130.4 million.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Southern Cross Gold Consolidated Ltd throws its weight behind Australia’s new A$1.2 billion Critical Minerals Strategic Reserve, spotlighting its Sunday Creek gold-antimony project as a key player in securing domestic supply and reducing reliance on China.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

Elevra Lithium unveils a staged, accelerated expansion plan for its North American Lithium mine, aiming to increase spodumene concentrate production to 315ktpa by early 2029 while lowering operating costs.

Revolver Resources has unveiled a compelling recommencement study for its Dianne Copper Mine in Queensland, forecasting over $125 million in pre-tax free cashflow from a four-year operation producing 14,330 tonnes of high-grade copper cathode.

Pharmaceutical manufacturer ANO has been hit with a US FDA Import Alert, joining several Australian peers amid wider regulatory tensions. The company is mobilising expert consultants and preparing a petition to lift the alert within weeks.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.